Targeting BRAFV600E with PLX4720 displays potent antimigratory and Anti-invasive activity in preclinical models of human thyroid cancer

Oncologist

Volumn 16, Issue 3, 2011, Pages 296-309

  Nucera, Carmelo ^a,e   Nehs, Matthew A ^a   Nagarkatti, Sushruta S ^a   Sadow, Peter M ^b   Mekel, Michal ^a   Fischer, Andrew H ^c   Lin, Paul S ^d   Bollag, Gideon E ^d   Lawler, Jack ^e   Hodin, Richard A ^a   Parangi, Sareh ^a  

^a Endocrine Surgery Unit   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d PLEXXIKON INC   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anaplastic thyroid cancer; BrafV600E inhibitor; Invasion; Metastasis; Mutation; Orthotopic; Primary human normal thyroid follicular cells

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; GLUTAMIC ACID; PLX 4720; PROTEIN PATCHED 1; PROTEIN RET; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; VALINE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN TPC 1; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; NONHUMAN; PAIRED BOX GENE 8; PRIORITY JOURNAL; THYROID CANCER; THYROID CELL; UPREGULATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; CELL GROWTH; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETIC TRANSFECTION; GENETICS; MALE; MASS SPECTROMETRY; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; PATHOLOGY; PHOSPHORYLATION; THYROID TUMOR; TUMOR CELL LINE;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FEMALE; GENOTYPE; HUMANS; INDOLES; MALE; MASS SPECTROMETRY; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THYROID NEOPLASMS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953021811     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0317     Document Type: Article

References (41)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology 2007. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, accessed September 2009.
2. Pacini F. Where do we stand with targeted therapy of refractory thyroid cancer?-utility of RECIST criteria. Thyroid 2008;18:279-280.
3. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148:936-941.
4. Santoro M, Melillo RM, Carlomagno F et al. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 2002;963:116-121.
5. Giordano TJ, Kuick R, Thomas DG et al. Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutationspecific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005;24:6646-6656.
6. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12: 245-262.
7. Frasca F, Nucera C, Pellegriti G et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008;15:191-205.
8. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
9. Emuss V, Garnett M, Mason C et al. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with BRAF. Cancer Res 2005;65:9719-9726.
10. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116: 855-867.
11. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009;21:296-303.
12. Mitsutake N, Knauf JA, Mitsutake S et al. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465-2473.
13. Begum S, Rosenbaum E, Henrique R et al. BRAF mutations in anaplastic thyroid carcinoma: Implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-1363.
14. Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-3046.
15. Meireles AM, Preto A, Rocha AS et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007;17:707-715.
16. Fischer AH, Taysavang P, Jhiang SM. Nuclear envelope irregularity is induced by RET/PTC during interphase. Am J Pathol 2003;163:1091-1100.
17. Boehm JS, Zhao JJ, Yao J et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-1079.
18. Nucera C, Eeckhoute J, Finn S et al. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res 2009;15:3680-3689.
19. Nucera C, Porrello A, Antonello ZA et al. B-Raf(V600E) and thrombospondin-promote thyroid cancer progression. Proc Natl Acad Sci U S A 2010;107:10649-10654.
20. Shih SC, Smith LE. Quantitative multi-gene transcriptional profiling using real-time PCR with a master template. Exp Mol Pathol 2005;79:14-22.
21. Nucera C, Nehs MA, Mekel M et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 2009;19:1077-1084.
22. Ji H, Wang Z, Perera SA et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933-4939.
23. Puxeddu E, Moretti S, Giannico A et al. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol 2003;148:505-513.
24. Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-4341.
25. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and onco- genic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209-221.
26. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430.
27. Salerno P, De Falco V, Tamburrino A et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010;95:450-455.
28. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009;94:1493-1499.
29. Tuttle RM, Leboeuf R. Investigational therapies for metastatic thyroid carcinoma. J Natl Compr Canc Netw 2007;5:641-646.
30. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:713-722.
31. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762.
32. Nucera C, Goldfarb M, Hodin R et al. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009;1795:152-161.
33. Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464: 427-430.
34. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-435.
35. Patel MK, Lymn JS, Clunn GF et al. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2107-2114.
36. Chandrasekaran S, Guo NH, Rodrigues RG et al. Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by _3_1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem 1999;274:11408-11416.
37. Iyer V, Pumiglia K, DiPersio CM. α3β1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: A novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 2005;118:1185-1195.
38. Majack RA, Mildbrandt J, Dixit VM. Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to plateletderived growth factor. J Biol Chem 1987;262:8821-8825.
39. Kwong LN, Chin L. The brothers RAF. Cell 2010;140:180-182.
40. Emery CM, Vijayendran KG, Zipser MC et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009; 106:20411-20416.
41. Yoshimoto K, Iwahana H, Fukuda A et al. Role of p53 mutations in endocrine tumorigenesis: Mutation detection by polymerase chain reactionsingle strand conformation polymorphism. Cancer Res 1992;52:5061-5064